OverviewSuggest Edit

The Company’s wholly owned clinical stage drugs include Filanesib in Phase II clinical trials, is indicated for Kinesin spindle protein (KSP), inhibitor for MM; ARRY-797 in Phase II clinical trials, indicated for p38 inhibitor for Lamin A/C-related dilated cardiomyopathy (LMNA-DCM); ARRY-502 in Phase II clinical trials, indicated for CRTh2 antagonist for asthma, and ARRY-614 in Phase I clinical trials, is indicated for p38/Tie2 dual inhibitor for myelodysplastic syndromes (MDS). In addition, the Company has 11 ongoing partner-funded clinical programs, including two MEK inhibitors, which are both in Phase III clinical trials, binimetinib with Novartis and selumetinib with AstraZeneca.

TypePublic
Founded1998
HQBoulder, US
Websitearraybiopharma.com
Employee Ratings3.4

Latest Updates

Employees (est.) (Dec 2017)209
Job Openings19
Revenue (FY, 2018)$173.8 M(+16%)
Share Price (Mar 2019)$23.6 (-1%)

Key People/Management at Array BioPharma

Ron Squarer

Ron Squarer

CEO
Jason Haddock

Jason Haddock

CFO
Andrew Robbins

Andrew Robbins

COO
Victor Sandor

Victor Sandor

Chief Medical Officer
Nicholas Saccomano

Nicholas Saccomano

Chief Scientific Officer
Curtis Oltmans

Curtis Oltmans

Executive Vice President, General Counsel and Secretary
Show more

Array BioPharma Office Locations

Array BioPharma has offices in Boulder, Miami, Boston, Phoenix and in 7 other locations
Boulder, US (HQ)
3200 Walnut St
Boston, US
Boston, MA, USA
Cambridge, US
125 Cambridgepark Dr #301
Charlotte, US
Charlotte, NC, USA
Chicago, US
Chicago, IL, USA
Detroit, US
Detroit, MI, USA
Show all (11)
Report incorrect company information

Array BioPharma Financials and Metrics

Array BioPharma Revenue

Array BioPharma's revenue was reported to be $173.77 m in FY, 2018
USD

Revenue (Q2, 2019)

82.5m

Gross profit (Q2, 2019)

81.8m

Gross profit margin (Q2, 2019), %

99%

Net income (Q2, 2019)

(11.4m)

EBIT (Q2, 2019)

(10.8m)

Market capitalization (15-Mar-2019)

5.2b

Closing stock price (15-Mar-2019)

23.6

Cash (31-Dec-2018)

147.1m

EV

5.1b
Array BioPharma's current market capitalization is $5.2 b.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

42.1m51.9m137.9m150.9m173.8m

Revenue growth, %

23%166%

General and administrative expense

21.9m31.4m36.3m39.3m58.5m

Operating expense total

117.7m130.3m220.1m252.9m303.7m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Revenue

14.2m14.1m7.8m6.1m16.2m35.4m43.0m39.3m44.5m33.3m29.7m42.2m66.4m56.9m82.5m

Cost of goods sold

195.0k786.0k

Gross profit

56.7m81.8m

Gross profit Margin, %

100%99%
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

68.6m55.7m56.6m125.9m114.7m

Accounts Receivable

5.4m6.3m39.3m31.3m32.1m

Inventories

5.2m6.4m6.1m

Current Assets

121.7m191.0m155.3m270.2m451.5m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Cash

65.0m47.2m52.2m46.8m68.1m141.5m56.4m57.3m62.5m65.8m62.8m83.7m295.4m65.1m73.9m130.5m147.1m

Accounts Receivable

1.0m5.7m4.4m6.0m4.9m2.1m13.5m64.8m62.9m33.9m43.1m32.5m26.6m30.0m44.2m44.4m22.2m

Current Assets

134.2m128.5m118.1m122.8m150.8m196.6m179.6m191.9m187.5m158.0m263.9m247.0m493.8m453.9m487.8m476.2m530.8m

PP&E

9.1m8.4m7.8m7.8m8.1m7.5m5.0m5.7m6.5m7.3m7.4m8.5m7.6m7.2m7.6m6.9m6.9m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(85.3m)9.4m(92.8m)(116.8m)

Depreciation and Amortization

4.5m3.7m1.5m2.1m

Inventories

Accounts Payable

Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Net Income

(15.7m)(32.1m)(57.0m)(27.6m)(36.2m)22.1m(21.0m)(24.2m)(22.7m)(28.6m)(23.3m)(35.3m)(72.0m)(94.9m)(24.8m)(36.2m)

Depreciation and Amortization

1.1m2.4m3.6m876.0k1.8m2.8m473.0k1.1m1.7m533.0k1.1m

Accounts Payable

12.1m15.6m5.9m6.5m7.8m8.9m

Cash From Operating Activities

(1.1m)(34.3m)(49.4m)(18.8m)(16.8m)21.5m(19.2m)(70.2m)(91.2m)(34.8m)(43.4m)
USDY, 2018

EV/EBIT

-475 x

EV/CFO

-118.4 x

Financial Leverage

1.9 x
Show all financial metrics
Report incorrect company information

Array BioPharma News and Updates

Array BioPharma Announces 15.3 Months Median Overall Survival from the Safety Lead-in of the Phase 3 BEACON CRC Trial of the Combination BRAFTOVI®, MEKTOVI® and ERBITUX® in BRAF-Mutant Metastatic Colorectal Cancer

BOULDER, Colo., Jan. 14, 2019 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced updated safety and efficacy results, including mature overall survival (OS), from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of BRAFTOVI®...

Array BioPharma to Present at the 37th Annual J.P. Morgan Healthcare Conference

BOULDER, Colo., Dec. 20, 2018 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will speak at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco. The public is welcome to participate in the conference through ...

Array BioPharma to Present at the 30th Annual Piper Jaffray Healthcare Conference

BOULDER, Colo., Nov. 20, 2018 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will speak at the 30th Annual Piper Jaffray Healthcare Conference in New York. The public is welcome to participate in the conference through a...

Array BioPharma to Present at the Stifel 2018 Healthcare Conference and the Jefferies 2018 London Healthcare Conference

BOULDER, Colo., Nov. 6, 2018 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will speak at the Stifel 2018 Healthcare Conference and the Jefferies 2018 London Healthcare Conference. The public is welcome to participate in...

Array BioPharma to Report Financial Results for the First Quarter of Fiscal 2019 on October 30, 2018

BOULDER, Colo., Oct. 23, 2018 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the first quarter of fiscal 2019 and hold a conference call to discuss those results on Tuesday, October 30, 2018. Ron Squarer, Chief Executive Officer, will lead the call....

Array BioPharma to Present at the 2018 Cantor Global Healthcare Conference

BOULDER, Colo., Sept. 25, 2018 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will speak at the 2018 Cantor Global Healthcare Conference in New York. The public is welcome to participate in the conference through a...
Show more
Report incorrect company information

Array BioPharma Blogs

Array BioPharma to Present at the 39th Annual Cowen Health Care Conference

BOULDER, Colo. , March 5, 2019 /PRNewswire/ --  Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer , will speak at the 39 th Annual Cowen Health Care Conference in Boston . The public is welcome to participate in the conference through a webcast on the

Array BioPharma to Present at the 8th Annual SVB Leerink Partners Global Healthcare Conference

BOULDER, Colo. , Feb. 21, 2019 /PRNewswire/ --  Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer , will speak at the SVB Leerink Partners 8 th Annual Global Healthcare Conference in New York.  The public is welcome to participate in the conference

Array BioPharma Reports Financial Results for the Second Quarter of Fiscal 2019

- Strong quarter for BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in U.S. with $22.7 million in net product sales, which represents quarter over quarter growth of 62% - - Combination of BRAFTOVI, MEKTOVI and ERBITUX® (cetuximab) demonstrated 15.3 months median overall survival in safety lead-in

Array BioPharma to Report Financial Results for the Second Quarter of Fiscal 2019 on February 5, 2019

BOULDER, Colo. , Jan. 29, 2019 /PRNewswire/ --  Array BioPharma Inc. (Nasdaq:  ARRY) will report financial results for the second quarter of fiscal 2019 and hold a conference call to discuss those results on Tuesday, February 5, 2019 . Ron Squarer, Chief Executive Officer, will lead the call.

Thomas Smith

Thomas Smith JorgeRendell.C… Thu, 01/17/2019 - 12:43 Thomas Smith Leerink

Paul Choi

Paul Choi JorgeRendell.C… Wed, 12/19/2018 - 17:37 Paul Choi Goldman Sachs
Show more

Array BioPharma Frequently Asked Questions

  • When was Array BioPharma founded?

    Array BioPharma was founded in 1998.

  • Who are Array BioPharma key executives?

    Array BioPharma's key executives are Ron Squarer, Jason Haddock and Andrew Robbins.

  • How many employees does Array BioPharma have?

    Array BioPharma has 209 employees.

  • What is Array BioPharma revenue?

    Latest Array BioPharma annual revenue is $173.8 m.

  • What is Array BioPharma revenue per employee?

    Latest Array BioPharma revenue per employee is $831.4 k.

  • Who are Array BioPharma competitors?

    Competitors of Array BioPharma include Recro Pharma, Durect and Zogenix.

  • Where is Array BioPharma headquarters?

    Array BioPharma headquarters is located at 3200 Walnut St, Boulder.

  • Where are Array BioPharma offices?

    Array BioPharma has offices in Boulder, Miami, Boston, Phoenix and in 7 other locations.

  • How many offices does Array BioPharma have?

    Array BioPharma has 11 offices.